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ABSTRACT
The main etiologies of dementia, a neurodegenerative disease, consist of:
Alzheimer’s Disease (AD), Vascular Dementia (VD), Frontotemporal Lobar Dementia
(FTD), and Lewy Body Dementia (LBD). AD the most common form of dementia is
the sixth leading cause of death in the US, where currently 5.3 million Americans are
diagnosed with Late-Onset and 95% of cases are 65 years and older. Early-Onset
represents the remaining 5% of cases where ages at diagnosis is younger than 65
years. AD is characterized by a progressive loss of neurons with impact on patient
cognition, function, and behavior.
The 2015 Alzheimer’s Association Report estimated direct and indirect costs of
AD and other dementias will reach $226 billion with an expected five-fold increase to
$1.1 trillion by the year 2050. With no treatment available that stops, or slows down
progression of the disease places the cost estimates of AD and dementia among the
most expensive chronic diseases.
The next generation of AD medications being investigated will target
progression of the disease. Disease-modifying medications (DMMs) are being
developed with a mechanism of action directed towards the main hallmarks found in
AD patients: the amyloid-beta (Aβ) plaques, and the tau tangles. Tolfenamic acid, a
non-steroidal anti-inflammatory (NSAID) drug, is being repurposed in the US as a
DMM for AD treatment; human clinical trials still pending. Aducanumab, a
monoclonal antibody, binds Aβ and increases its clearance; Phase III human clinical
trials are in progress. DMMs are anticipated to improve cognition, function and
behavior.

The objectives, hypotheses, methods and results of this dissertation follow the
manuscript format, and are three fold:
Manuscript 1: The objective was to estimate cost-effectiveness of novel
disease-modifying medication (DMM) compared to standard medication currently
used in the treatment of Alzheimer’s disease. The hypothesis was that the DMM
option will show a favorable cost-effectiveness when compared to standard care.
Using a Markov Model with a study population comprised of a hypothetical 1000
patients, 65 years and older, we evaluated quality life years (QALYs) gained by the
new DMM and an appropriate price to develop a cost-effectiveness framework for the
new product. In the Markov model we were able to determine an increase in QALYs
when compared to standard of care with a cost value for DMM much higher than
current standard care while still showing cost-effectiveness as a new treatment option.
Manuscript 2: The objective was to determine affordability to payer’s budget
i.e. insurance or hospital upon the introduction of the new cost-effective diseasemodifying medication (DMM) class in treatment of Alzheimer’s disease. The
hypothesis was that the introduction of DMM will have minimal budgetary changes to
direct costs incurred by payers. Using a 1-year budget impact analysis, a prospective
short-term analysis was conducted using Optum Clinformatics™ Data Mart (January
2010-Decemeber 2012), a large national insurer database with administrative health
claims information, with a study population of patients 65 years and older. Two
scenarios are to be compared: current mix treatment costs of medications used in
Alzheimer’s versus a new mix treatment cost that included the addition of DMM to
current mix treatment. The difference in total payer cost of the two scenarios

represents the budget impact of the new therapy implementation, allowing us to
predicate future cost of new treatment mix. The study estimated a total per-memberper-month (PMPM) treatment cost pre- and post- introduction of DMM that would be
affordable to payer’s and recommended to be added to formulary.
Manuscript 3: The objective was to describe prevalence, incidence, and direct
total cost predictors associated with Early-Onset Dementia (EOD) and its etiologies.
The hypothesis was that Alzheimer’s disease would be main predicator of overall
EOD direct cost. We conducted a retrospective cohort study using Optum
Clinformatics™ Data Mart (January 2010-Decemeber 2012), a large national insurer
database with administrative health claims information, with a study population of
patients 21-64 years and older. Total cost components include: physician visits,
hospital visits, nursing home care, and prescription drugs associated with EOD
treatment. Using a Generalized Linear Model (GLM) to assess the relationships
between total cost and the covariates of interest, we identified age, geographical
regions, EOD subtypes, and comorbidities as total cost predictors of EOD.
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PREFACE

This dissertation is written in the manuscript format, and is comprised of three
manuscripts, which evaluated (1) cost-effectiveness of new novel disease-modifying
medications in Alzheimer’s disease, (2) the affordability to payers of said new novel
medications, (3) the direct cost predicators in Early-Onset Dementia.
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1.1 Abstract
Our purpose was to estimate the cost-effectiveness of novel disease-modifying
medication (DMM) in patients with Alzheimer’s disease. A 20 year Markov decisionanalysis model was developed using data from previous studies and databases to
measure lifetime costs and quality-adjusted life years of DMM compared with current
standard of care drug therapy. The modeled population was a hypothetical cohort of 55
year-old patients assigned to the initial Mild Cognitive Impairment (MCI) health state
in our Alzheimer’s disease model. Health states and progression were defined
according to the Clinical Dementia Rating Scale (CDR). Patient movement between
the health states was simulated using transition probabilities derived from published
sources. The willingness-to-pay threshold was $100,000/quality-adjusted life-year
gained.
In the base case, costs for the proposed DMM were $22,000 (SD=$5,000) producing a
quality-adjusted life years (QALY) estimate at 8.97 (SD=3.50), while the standard of
care treatment yielded 7.24 QALYs (SD=3.38), having an incremental cost
effectiveness ratio of $89,222/QALY. In the Monte Carlo probabilistic sensitivity
analysis the DMM option was cost-effective in 92% of the simulations versus 8% of
the simulations for the standard of care option.
The cost-effectiveness of novel DMM in Alzheimer’s patients will depend on
medication pricing and prolonging time spent in the community against early entry to
nursing home care.
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1.2 Introduction
Alzheimer’s disease (AD) affects 5.3 million Americans with 95% of patients
being 65 years or older, two-thirds being female, and with early symptoms showing 5
to 10 years prior to official diagnosis.1-3 The prevalence of AD is projected to increase
by 40% in the next 10 years reaching an estimated 14 million patients by the year
2050.1-3 The incidence of AD increases with age and doubles every 5 years after the
age of 65.1-4 In 2015 a projected 700,000 people aged 65 or older will have AD as
cause of death, and although deaths from other major chronic diseases (e.g. HIV) have
experienced drastic declines it was reported that between 2000-2012 there was a 68%
increase in cause of death attributed to AD.5,6 The most common cause of death in
patients with AD is pneumonia.5,6
The 2015 Alzheimer’s Association report estimated direct and indirect costs of
AD and other dementias will reach $226 billion with an expected five-fold increase to
$1.1 trillion by the year 2050. These estimates place AD and dementia as one of the
most expensive chronic diseases. Current AD medication cost to payers range between
$2500 and $3500 annually.7,8
AD progression is characterized by the accumulation of amyloid-beta (Aβ)
plaques and tau tangles leading to neuronal death and loss.9-11 The amyloid precursor
protein (APP) is cleaved via enzymes into the Aβ peptides which then aggregate,
deposit into plaques, and initiate the pathology of AD.9-11 In addition to the Aβ
plaques tau protein is hyperphosphorylated resulting in aggregation and tau tangle
formations initiating AD pathology.12-14 These processes are the leading causes of
decline in cognitive function, behavior, and performance of daily activities in patients
3

with AD.12-14 The mechanism of action of current AD medications do not target either
of the previous mentioned triggers of AD development and progression.8,15,16
The next generation of AD medications being investigated will target
progression of the disease.15-17 Disease-modifying medications (DMMs) are being
developed with a mechanism of action directed towards the main hallmarks found in
AD patients: the amyloid-beta (Aβ) plaques, and the tau tangles.15,16 Tolfenamic acid,
a non-steroidal anti-inflammatory (NSAID) drug, is being repurposed in the US as a
DMM for AD treatment; human clinical trials still pending.15,16 Monoclonal antibody
drug class, e.g. Aducanumab along with other anti-Aβ trial drugs, target Aβ and
increases its clearance; Phase III human clinical trials are in progress for some of these
new drug therapies.17-19 Majority of these new therapies will be targeting the early
mild stages of AD, anticipating improvement in cognition, function and behavior.17-19
Early detection of AD and providing DMM therapy has potential of limiting AD
progression, spending more time in the earlier less severe and costly stages of disease
and increasing time in the community.20,21
Predicting the efficacy of novel DMM for AD will exceed current treatment
options, certainly these medications will be priced at a premium. We assessed the
value of DMM by conducting a cost-effectiveness analysis. We used Markov
modeling to simulate the anticipated states of disease progression, and model patients
with AD transitioning through the different health states predicting clinical outcome
and cost of DMM therapy.
1.3 Methods
This study design was a Markov model utilizing published clinical data and
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registry databases as primary data source for: cost, utility values, transition
probabilities, and medication efficacy converted to relative risk reduction.
The study population was comprised of a hypothetical cohort of patients, 55
years-old, assigned to the initial Mild Cognitive Impairment (MCI) health state of the
Markov model. Patient movement between the health states was simulated using
transition probabilities reflecting rates of clinical progression, assigning cost to each
health state..20-23 (Figure 2)
The study’s model was built on a set of specific health states in which a patient
transitioned through while occupying only one health state at any given time.24-26 The
model investigated the transitions through several time specified cycles where patients
entered, stayed, or exited the health state; each health state cycle lasting for 1 year and
over a 20 year life span of the entire model.24-26 Transition probabilities determined the
movement among the health states between the two arms of our model,
DMM vs Standard of Care, as informed by observed rates of disease progression for
patients treated with currently available medications, as determined in clinical and
epidemiologic research.24-26 Costs and utility values were assigned to each health state,
calculated at each cycle, and then aggregated to estimate cost-effectiveness of each
option. Incremental Cost-Effectiveness Ratios (ICERs) for both the DMM and
Standard of Care were used for comparison. The DMM arm of the model represents
any of the current novel proposed DMMs that are in clinical trials, while our Standard
of Care arm represents the available Alzheimer’s medication therapy available,
currently marketed in the U.S.27,28 e.g. Donepezil and Memantine.
As defined by the National Institute on Aging, of the US Department of Health
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and Human Services, characterizations of AD progression; our model uses five
distinctive health states: MCI, mild AD, moderate AD, severe AD, and death.20-22,29 All
five health states were defined using the Clinical Dementia Rating (CDR) Scale.20,21,29
The CDR Scale is a universal measure for patient cognitive function determined by
assigning scores to questions covering six fields: memory, orientation, judgement &
problem solving, home & hobbies, community affairs, and personal care.30 CDR
scores range from a minimum of 0 to a maximum of 3, and are categorized in our
study as follows: 0.5 (MCI) 1 (mild AD), 2 (moderate AD), and 3 (severe AD).22,30-32
Scores were calculated from the Consortium to Establish a Registry for Alzheimer’s
disease (CERAD) database, and used in prior studies.30,31 The transition probabilities,
utility values, and cost analysis studies, from which we extracted our input parameters,
used CDR as their scale to define the AD health states.22,31-33
The model began with a hypothetical 1000 patient population distribution
assigned to the initial MCI health state and simulates patient movement through the
progressive states using transition probabilities.20-22,34 The transition probabilities
defined the rate of progression through the health states; for example a patient in
moderate AD can remain in that same state, move to severe state, or enter the
absorbing state of death which they do not exit.20-22,34 No movement backwards to a
less severe state was permitted.
The simulated patient cohort was assigned transition probabilities based on
therapy received: DMM or Standard of Care. Completion of each individual cycle
produced an estimated cost and quality-adjusted life years (QALY) gained, for
treatment comparisons. The measure effect was in incremental cost/QALY gained,
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assessing the influence of DMM treatment on AD progression as compared to
Standard of Care.
Model parameter inputs included: costs (medications, outpatient visits,
inpatient stays, and long-term facility e.g. nursing home); utility values used for
quality-adjusted life years (QALY) gained calculation, transition probabilities, and
relative risk (RR) representing DMM treatment effect. With most of the DMM under
consideration still undergoing clinical trials we made a RR assumption value of 0.5,
predicting that DMM will be at least as effective as Donepezil where the RR of
transitioning from mild to moderate AD was 50% less in treatment group when
compared to placebo group.35 We assumped that DMM will in fact impact progression
of the disease unlike current treatments available.17,36 The RR value was applied to
produce new transition probabilities, in the DMM arm of the model, to simulate the
impact of new therapy. From the previous unsuccessful DMM monoclonal antibody
clinical trials, and the current ongoing trials the population target is those in the early
stages of Alzheimer’s that will benefit most from DMM therapy i.e. MCI or mild
Alzheimer’s patients17-19,36. We applied the RR to transition probabilities, in DMM
arm, to health states of MCI and Mild AD, reducing transition probabilities from the
earlier states to the more severe states. Published literature was primary source for:
cost, utility values, transition probabilities, and RR. Micromedex Redbook database
was the source of price for Standard of Care medications, using Average Wholesale
Price (AWP) as our benchmark. (Table 1)
To predict DMM future market cost we considered Multiple Sclerosis (MS)-a
neurodegenerative illness which uses disease-modifying medication type therapies.
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The price of new therapies in MS, which are mainly of the monoclonal drug class, are
usually 5 times higher than current medication treatments.37 Average cost of
monoclonal antibodies currently on the market, in other disease states, were also
considered to aid in the assumption as to the cost of these proposed new therapies in
AD. Using this rationale the study assumed a cost of $22,000 per year, included in
which was cost of physician visit where administration of medication would occur.
Descriptive statistics were presented for AD costs, while the simulation following
patient movements between the health states calculates expected costs and qualityadjusted life years (QALY) gained. This was carried out for each specific health state
at each cycle the model goes through producing an incremental cost per QALY for
each state, weighted by the proportion of patients in the health state before totaling
across all cycles.38-40 The process described uses a Monte Carlo Simulation. The
Monte Carlo simulation allows the above mentioned process to be repeated 1000 times
through the time horizon of the entire model.38-40 The incremental cost/QALY
produced was compared to the Willingness-to-Pay/QALY ($100,000 per QALY) to
determine cost-effectiveness of DMM treatment.38-41
Probabilistic sensitivity analysis (PSA) was used to reflect input parameters’
uncertainty.38,42,43 Input parameters’ distributions were assigned as follows: beta
distribution for utilities, gamma distribution for DMM cost, and log-normal applied to
the Relative Risk and transition probabilities.40,42
PSA in the Monte Carlo simulation chose a random value from each of the
input parameters from the specified distribution assigned for each model iteration.40,42
Each single model run generated a single incremental cost-effectiveness ratio (ICER)
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value, and with repeating the process 1000 times produced a distribution of ICERs.
The resulting ICERs with confidence intervals was plotted on a cost-effectiveness
plane graph. Given the time value of costs and QALYs, a dollar and QALY is worth
more today than it would be tomorrow, a standard discount rate of 3% to present value
of future costs and QALYs was incorporated.40,42 Model building and all statistical
analysis were performed using TreeAge Software, Inc. version Pro 2016 (Williamston,
MA).
1.4 Results
Diagram representation of the Markov model (Figure 2) illustrates that all
patients start at 55 years-old with Mild Cognitive Impairment (MCI). Patients’ cycle
between health states until death occurs or the 20-year model time horizon was
reached. The length of each cycle was 1 year. Illustrated in the diagram was the
decision node (square), chance nodes (circles) directed by transition probabilities,
Markov nodes (circle with ‘M’), and terminal nodes (triangles). Markov branch for the
standard of care (SC) therapy was identical to the disease-modifying medication
(DMM) branch shown.
In the base case (Table 2), quality-adjusted life expectancy (QALY) for our diseasemodifying medication (DMM) was 8.98 (SD=3.32) versus the standard of care (SC)
7.41 (SD=3.28). When compared to SC, DMM produced an additional 1.57 QALY at a
cost of $154,852, estimating an incremental cost-effectiveness ratio (ICER) of $89,222
per QALY, and below our established willingness-to-pay (WTP) threshold of $100,000
per QALY.
One-way sensitivity analyses were conducted for our model parameters to
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determine the variables with most impact on our results. Key input parameters were
varied one input at a time while holding other constant at their base-estimates.
Sensitivity analyses was conducted on costs, probabilities, and utilities.
A tornado diagram (Figure 6) illustrating the cost variables in descending order of
influence was developed. The horizontal bars in the diagram represent net monetary
benefit values expected from the range of values evaluated for each of our influential
model parameters. The vertical black line on the bars represents a change in the DMM
arm when the variable starts producing net monetary benefit. Parameters with most
impact on the model were costs: price of the DMM therapy; probabilities: transition
probability from Mild Cognitive Impairment (MCI) to Mild AD; utilities: utility value
for MCI, and the relative risk reduction (RR) parameter.
The Monte Carlo Probabilistic Sensitivity Analysis (PSA) incorporated both intraindividual and parameter uncertainty respectively produced results presented in Table
2. Using the WTP of $100,000 our DMM produced an ICER of $89,812/QALY with
92% of the iterations showing cost-effectiveness when compared to 8% in SC. (Figure
4). The cost-effectiveness acceptability (CEA) curve also illustrates the probability
that DMM therapy will be cost-effective at varying WTP thresholds for a patient
(Figure 5).
Table 3 presents the sensitivity analyses for the ICERs associated when varying
parameter assumptions. When DMM cost was considered we estimated an ICER of
$53,627/QALY and $128,549/QALY for 10% decrease and 10% increase in the price
of the drug therapy, respectively. The results shown in other parameters were sensitive
to varying the assumptions of their values. Varying the probability of disease
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progression (MCI to Mild AD) estimated ICERs of $76,695/QALY and
$106,645/QALY for 10% decrease and 10% increase, respectively. Utility weight for
MCI had ICERs of $105,651/QALY and $81,284/QALY for 10% decrease and 10%
increase, respectively.
1.5 Discussion
Our study demonstrated that a disease-modifying medication (DMM) delaying
the cognitive decline, increasing time spent in the less severe and costly health states
of Alzheimer’s disease (AD) can possibly be cost-effective when compared to current
medication therapies. This study can provide a framework or working design that
estimates the assumed and possible effect of these newly proposed novel DMM that
are currently in clinical trial pipelines. The study used published data to build the
decision, but with deficiencies in direct evidence on DMM effects or possible costs
associated with the new therapy. Currently there are several anti-amyloid beta
monoclonal antibodies in the pipeline of companies, with some of the more recent
trials reaching Phase III but unfortunately not being able to show progress.17-19,36,44
Aducanumab, a monoclonal antibody, is currently the most promising of the pipeline
products showing credible progress in Phase III trials in the early less several AD
health states18,19 i.e. MCI and Mild AD. Given that no such DMM is on the market yet
we had to make an assumption of expected price, using sensitivity analysis to
determine with all our input parameters and WTP level that a price as high as $23,189
per year will maintain cost-effectiveness favorability of new therapy. In similar
manner, we estimated that a relative risk reduction of 0.546 would maintain costeffectiveness for new therapy. Despite these uncertainties our model framework can
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still provide hypothetical information on what to expect from DMM, and the model
inputs can be updated once more of the clinical trial results become available and
published. Additional uncertainty highlighted in our model were the direct cost inputs
of the various health states of AD i.e. mild or moderate, community or nursing home.
Rice et al. 1994 was one of the very few studies available that broke down the costs of
AD by level of severity in a population in North California. Similarly, two review
studies by Mauskopf et al. (2010 and 2011), estimating the cost of AD in the U.S. as
well as the association of cost with disease severity provided a source of cost
information for our model to make up for the lack of current cost studies in AD.45,46
The use of a claims database of a U.S. population might provide a solution and useful
information in AD cost studies, but patients are not diagnosed based on disease
severity and are usually recorded as AD and not as mild AD or moderate AD. The
severity of disease states might be recorded in the medical record as notes but not
captured in a database. Hence, a study similar to the Rice et al. 1994 study that
categorizes patients by disease severity in a healthcare setting and follows them as
they progress to capture their costs would be ideal way to capture more definite and
specific costs.
An aspect of our study to consider is that using DMM patients are expected to spend
more time in the less severe states spending more time in the community setting, and
if considering a societal prospective then we would predict a delay in nursing home
placement and its cost but at the expense of increased unpaid family caregivers to aid
with the patients.22 Our model focuses primarily of direct cost of care, when the
biggest factor contributing to the rising cost of AD are the indirect costs; costs
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associated with unpaid family caregivers, loss of productivity associated with both
patients and caregivers.22,45 When considering our study using a payer e.g. Insurance
perspective we should be cautious when trying to generalize it to an insurer or a
managed care plan. Given the uncertainty in relative risk reduction proposed for these
DMM still in clinical trials, the utility values based on current AD status which we
would expect to change with the slowing down of cognitive decline, and the cost
information based on several older studies we are restrained when interpreting our
results.
1.6 Limitations
This study provides a look into complexity of trying to model a chronic
condition such as AD. All the assumptions, inputs, and sensitivity analysis are to be
considered carefully given the lack of current DMM efficacy, cost, or impact on utility
values. Our basic assumption was that DMM will work particularly well in the early
less severe stages of AD, despite the several setbacks in clinical trials during the past
years but with still compounds being developed in the pipeline. The direct costs our
study used are dependent on the U.S. health system and might not be generalizable to
other countries given the wide range of different health insurance systems available.
The utility values (QALYs) were not validated in any trial using DMM so we have no
information on how the DMM will affect utility values or how they will change as
disease progresses. Side effects and their costs are usually part of cost-effectiveness
calculations, however with DMM still in clinical trial phases we yet to have access to
such information and being a simulation no such information was added to our model.
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1.7 Conclusion
Our model results, using available data, showed that future disease-modifying
medications in Alzheimer’s disease may be cost-effective when adopting a
willingness-to-pay of $100,000, and adding additional quality-of life year gained to
patients. We conclude that at cost of $23,000 or less and relative risk reduction of
0.546 or more disease-modifying medications would be cost-effective. Considering
current evidence and developments of these medications and other interventions, we
can update and re-evaluate the cost-effectiveness studies for Alzheimer’s disease in the
future.
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Figure 2. Schematic representation of the Markov model framework of DiseaseModifying Medication (DMM). Patients cycle between health states until death
occurs or 20-year model-time horizon is achieved. Decision node (square), chance
nodes (circles) directed by transition probabilities, Markov nodes (circle with
“M”), and terminal nodes. Standard of Care (SC) branch is identical to DMM
branch

24

Table 1. Projected Costs, Quality Adjusted Life Years (QALYs), and Incremental
Cost Effectiveness Ratios (ICERs) comparing Disease-Modifying Medication
(DMM) Therapy with current Standard of Care (SC) Therapy
Base Case
Total Cost (SD)

QALY (SD)

ICER

Standard of Care (SC)

$446,918 ($317,108)

7.24 (3.38)

…*

Disease-Modifying
Medication (DMM)

$601,770 ($446,917)

8.97 (3.5)

$89,222/QALY

Total Cost (SD)

QALY (SD)

ICER

Standard of Care (SC)

$447,817 ($9,792)

7.46 (0.68)

…*

Disease-Modifying
Medication (DMM)

$596,616 ($10,902)

9.11 (0.98)

$89,812/QALY

Probabilistic Sensitivity
Analysis (PSA)

ICER indicates incremental cost-effectiveness ratio;
QALY, quality-adjusted life year; SD, standard deviation
*SC is the reference
therapy for ICER
calculation
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Figure 3. Scatterplot of Disease-Modifying Medication (DMM) and the Standard
of Care (SC). Illustrates the Total Cost (y-axis) and Total Quality-Adjusted Life
Year (QALY) gained (x-axis) during the time-horizon of the model. DMM
(purple) shows higher QALYs gained at higher Total Cost when compared to SC
(green)
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Figure 4. Scatterplot of Disease-Modifying Medication (DMM) versus Standard
of Care (SC). Showing that with a Willingness-to-Pay (WTP) of $100,000
(represented by dash line ---) per Quality-Adjusted Life Year (QALY), 92% of
model iterations are below the WTP threshold and favoring the DMM Therapy
arm of the Markov model and estimating an additional 1.5 to 1.82 QALY
through the time-horizon of the model
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Figure 5. Cost-Effectiveness (CE) Acceptability Curve Represents Probability
that a Treatment will be CE (percentage iterations (y-axis) for which treatment
was CE) at varying Willingness-to-Pay Thresholds (x-axis). The amount, in
dollars, payer willing to pay to pay to achieve an additional quality-adjusted life
year

DMM – Disease-Modifying Medication (blue)
SC – Standard of Care (orange)

28

Table 2. Sensitivity Analyses
Incremental Cost Effectiveness Ratio (ICER, $)
Parameters

Base Case

$89,222

Relative Risk Reduction (Drug Effect)
10 % Higher

$87,977

10 % Lower

$107,455

DMM cost (Drug Cost)
10% Higher

$53,627

10% Lower

$128,549

Utility Weight (QALY for MCI)
10% Higher

$81,284

10% Lower

$105,651

Probability of Disease Progression (MCI to Mild AD)
10% Higher

$106,645

10% Lower

$76,695
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Figure 6. Tornado Diagram Represents Net Monetary Benefit (NMB) Values
Expected from a Range of Values Evaluated for each Variable with Impact on
the model. The Vertical black line represents the NMB Value that occurs where
change to our preferred treatment i.e. Disease-Modifying Medication happens for
the given variable

uMCI – Utility Value Mild Cognitive Impairment (MCI)
cDMM – Cost of Disease-Modifying Medication (DMM)
RR – Relative Risk (RR) for DMM
pMCI1toMild1 – Transition Probability of Disease from Mild Cognitive Impairment (MCI) to
Mild Alzheimer’s
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APPENDIX A. Decision Model Inputs: probabilities, costs, and utilities for both
Arms of the Markov Model; Standard of Care (SC) and Disease-Modifying
Medication (DMM)
Standard of Care (SC)
Item
Annual Transition Probabilities
Stage to Stage
MCI to MCI
MCI to Mild
MCI to Moderate
MCI to Severe
MCI to Death
Mild to Mild
Mild to Moderate
Mild to Severe
Mild to Death
Moderate to Moderate
Moderate to Severe
Moderate to Death
Severe to Severe
Severe to Death
*Costs, $
By Stage and Setting
MCI:
Community
Nursing Home
Mild:
Community
Nursing Home
Moderate:
Community
Nursing Home
Severe:
Community
Nursing Home
Other Costs
Medications:
Donepezil
Memantine
Quality-of-Life Weights (Utility)
By Stage
MCI

Estimate

Data Source

0.88
0.088
0.01
0.008
0.014
0.79
0.141
0.023
0.046
0.777
0.083
0.14
0.782
0.218

33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50

$8,000
22, 45, 49
Not Reported
$11,000
$67,000

22, 45, 49
22, 45, 49

$14,000
$73,000

22, 45, 49
22, 45, 49

$23,000
$78,000

22, 45, 49
22, 45, 49

$3,000
$2,000

AWP
AWP

0.76

47, 48
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Mild
Moderate
Severe
Disease-Modifying Medication (DMM)
Item
Annual Transition Probabilities
Stage to Stage
MCI to MCI

0.69
0.53
0.38

47, 48
47, 48
47, 48

Estimate

Data Source

0.933

Author
Calculations†
Author
Calculations†
Author
Calculations†
Author
Calculations†

MCI to Mild

0.044

MCI to Moderate

0.005

MCI to Severe

0.004

MCI to Death
Mild to Mild

0.014
0.872

Mild to Moderate

0.0705

Mild to Severe

0.0115

Mild to Death
Moderate to Moderate
Moderate to Severe
Moderate to Death
Severe to Severe
Severe to Death
*Costs
By Stage and Setting
MCI:
Community
Nursing Home
Mild:
Community
Nursing Home
Moderate:
Community
Nursing Home
Severe:
Community
Nursing Home
Other Costs

0.046
0.777
0.083
0.14
0.782
0.218

Author
Calculations†
Author
Calculations†
Author
Calculations†
33, 50
33, 50
33, 50
33, 50
33, 50
33, 50

$8,000
22, 45, 49
Not Reported
$11,000
$67,000
$14,000
$73,000

22, 45, 49
22, 45, 49
22, 45, 49
22, 45, 49

$23,000
$78,000

22, 45, 49
22, 45, 49
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Medications:
Donepezil
Memantine
Disease-Modifying Medication (DMM)
Quality-of-Life Weights (Utility)
By Stage
MCI
Mild
Moderate
Severe
Effect of Disease-Modifying Medication
MCI-to-Mild Transition

$3,000
$2,000
$22,000

AWP
AWP
Author
Assumptions‡

0.76
0.69
0.53
0.38

47, 48
47, 48
47, 48
47, 48

0.5

Author
Assumptions‡
Author
Assumptions‡
Author
Assumptions‡
Author
Assumptions‡
Author
Assumptions‡

MCI-to-Moderate Transition

0.5

MCI-to-Severe Transition

0.5

Mild-to-Moderate Transition

0.5

Mild-to-Severe Transition

0.5

* Costs were inflated and rounded up to estimate 2016
dollar values
AWP- Average Whole Sale Price. Using Micromedex Red
Book
† Author Calculations using an assumed relative risk
reduction of 0.5
‡ Author Assumption using current treatment effectiveness, costs, and proposed
medications undergoing clinical trials
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2.1 Abstract
A new therapeutic class of disease-modifying medications (DMM) are now
being developed for the management of Alzheimer’s disease (AD). The objective of
our study was to estimate the future financial consequences on a U.S. health care plan,
having a population size of 2.6 million, after the introduction of proposed novel
DMM. A 1- year budget impact model, estimating percentage of patients on current
AD medications and quantities filled were measured using the 2010-2012 Optum
Clinformatics™ Data Mart; a large national insurer database with administrative
health claims information from a private health plan in the U.S. We identified 436
patients with an AD diagnosis, and having filled specific AD medications during the
2012 study period. Total budget costs of before and after the introduction of the
proposed DMM were estimated in addition to the incremental changes in the permember-per-month (PMPM) cost. Sensitivity analyses were performed to evaluate the
impact of varying percentage of patients receiving AD medications, the price of new
proposed medication, percentage of patients switching from current therapy to new
medications, percentage of patients adding the new medication to their current therapy,
and percentage of new cases utilizing the new medication therapy. The expected
annual medication budgetary cost for AD medication utilization including the DMM
was $5,040,748 compared to $1,004,954 cost prior to the including DMM,
representing a 5-fold increase. The total incremental medication cost was $0.1616
PMPM, an increase from the $0.0322 PMPM cost before the DMM was introduced.
Using administrative claims database to estimate AD medication cost and utilization,
the introduction of novel DMM therapy will have a substantial effect on both the total
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and PMPM cost for AD medication budget. Given the importance of affordability of
new treatments to decision and policy-makers greater attention and planning needs to
be afforded to the expected sizable change predicted to occur with introduction of new
novel DMM therapy.
2.2 Introduction
Currently there is no cure for Alzheimer’s disease (AD), guidelines by both the
American College of Physicians and the American Academy of Family Physicians
divide treatment for AD into 2 medication categories1,2: Acetylcholinesterase
Inhibitors (AChEIs) e.g. Donepezil and N-methyl-D-aspartate (NMDA) e.g.
Memantine. The AChEIs prevent the breakdown of acetylcholine, a neurotransmitter
required for neuronal function, and help increase levels of the declining
neurotransmitter due to neuronal loss.1-3 The NMDAs reduce levels of glutamate
receptor activation and decrease neuronal dysfunction.1-3 The use of these therapeutic
agents as monotherapies or in combination during various stages of AD improve
cognition and daily functioning scale score slightly, but do not slow down progression,
decline in cognition, or cure AD.3-5
AD progression is characterized by the accumulation of amyloid-beta (Aβ)
plaques and tau tangles leading to neuronal death and loss.6,7 These hallmarks, Aβ and
tau tangles, are the targets of new investigational disease-modifying medication
(DMM), currently undergoing clinical trials, trying to slow AD progression and reduce
cognitive decline.4,5,8,9 Monoclonal antibody drug class, e.g. Aducanumab along with
other anti-Aβ trial drugs, target Aβ and increases its clearance; Phase III human
clinical trials are in progress for several of these new drug therapies.5,9,10 Majority of
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these new therapies will be targeting the early mild stages of AD, anticipating
improvement in cognition, function and behavior.5,9,10 With the efficacy of proposed
DMM monoclonal anti-body therapy expected to target the underlining causes of AD,
these DMM are expected to be priced at a premium. Current AD medications, AChEIs
and NMDAs, cost to payers range between $2500 and above $3500 annually. With
limited resources, decision makers have to determine the future budgetary impact with
the addition of new therapies, and judge competing treatments on both clinical and
cost effectiveness.
2.3 Methods
This study design was a 1-year retrospective before and after budget impact
analysis used to estimate the medication treatment cost of Alzheimer’s disease (AD)
before and after the introduction of a proposed disease-modifying medication (DMM).
Pharmacy claims data from Optum Clinformatics™ Data Mart served as the primary
data source for estimates of cost and utilization for current AD medications. Optum
Clinformatics Datamart™, a large national insurer database with administrative health
claims information for approximately 19 million patients, collected from January 2010
to December 2012.
The study population was comprised of continuously enrolled patients, from
2010 to 2012, who were 55 years and older with AD diagnosis and had an AD specific
medication prescription e.g. AChEIs or NMDAs filled during the 2012 year.
Population selection was as follows: all continuously enrolled patients who
were at risk (55 years and older 4,5), with a diagnosis of AD in accordance with the
International Classification of Disease 9th Edition Clinical Modification [ICD-9-CM]
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medical codes (AD ICD-9-CM code 331.0). Relevant codes were reviewed and
selected from the Agency for Healthcare Research and Quality (AHRQ), using the
Clinical Classification Software (CCS) from the Healthcare Cost and Utilization
Project (HCUP). The Clinical Classification Software (CCS) for ICD-9-CM is a tool
on the HCUP website, sponsored by AHRQ, which provides over 14,000 diagnosis
codes and 3,900 procedure codes. AD patients who were enrolled during 2012 and
met the age criterion of 55 years and older, and had AD specific medications filled
during the 2012 year made up our cohort used for analysis.
AD specific medications considered were AChEIs: Aricept (donepezil), Exelon
(galantamine), Razadyne (rivastigmine), and NMDAs: Memantine. During 2012
Namenda was only available as brand with the generic (memantine) not entering the
market until 2014, and the new Namzaric (donepezil/memantine) not available until
2016. Namenda XR also did not become available till 2014. We expect the price of
Namenda XR and Namzaric to be comparable to Namenda. The medications collected
from our database captured all formulations and dosage strengths that were prescribed.
The current or before addition of DMM mix (2012) of medications were categorized
as; AChEIs monotherapy, NMDA monotherapy, or AChEIs plus NMDA dual therapy
and the same categorization was completed for the new or after addition of DMM
mix.1,3
Two scenarios were compared: current mix treatment costs consisted of
medication costs before DMM available on market, and the new mix treatment after
following DMM introduction to the market. (Figure 1)
Current treatment mix costs was based on the 2014 prices of our Optum
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Clinformatics™ Data Mart databases as our baseline. The costs for each of our
medication categories (AChEIs, NMDA, and AChEI+NMDA) represented amount
charged to the insurer, minus patient coinsurance, copay or patient out of pocket
payments towards their deductible. Current mix included: total number of
prescriptions for each medication category, the number of patients utilizing the
prescriptions, and an estimate mean cost of per prescription along with per patient
prescription utilization mean for each of our medication category was determined.
New treatment mix was developed using 3 assumptions: 2% of newly
diagnosed AD patients measured as coming into the health plan at the start of the year,
20% of patients on current treatment category (AChEIs, NMDA, and AChEI+NMDA)
will switch to the new DMM therapy, and 10% of patients on current treatment
category (AChEIs, NMDA, AChEI+NMDA) will add the new DMM therapy to their
current mix. Patients with Cardiac arrhythmias were contraindicated to start, switch, or
add new DMM monoclonal antibody therapy per the clinical trial results conducted o
these newer medications.4,10 Patients who switched have their prescriptions and its
costs subtracted from the new mix total cost and prescription count, replaced with the
DMM cost and prescription count. Data from current and previous clinical trials on
proposed monoclonal anti-body DMM therapy proposed a one-time infusion of the
medication every 4 weeks.4,5,10 Current AD medications, AChEIs and NMDAs, cost to
payers range between $2500 and above $3500 annually.3,11 To predict DMM future
market cost we considered Multiple Sclerosis (MS)-a neurodegenerative illness which
uses disease-modifying medication type therapies. The price of new therapies in MS,
which are mainly of the monoclonal drug class, are usually 5 times higher than current
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medication treatments.12 Average cost of monoclonal antibodies currently on the
market, in other disease states, were also considered to aid in the assumption as to the
cost of these proposed new therapies in AD. Using this rationale the study assumed a
cost of $24,000/year or $2,000 for a monthly prescription. We can assume a single
prescription a month for 12-months of the new DMM therapy to determine the annual
total cost with a per prescription cost of $2,000 that was previously assumed.
New treatment mix costs, after DMM introduction include: the cost of the
newly diagnosed patients entering the health plan with no current therapy starting
DMM, cost of current mix that was not lost to patients switching, and cost of patients
that added the new therapy to their current medications. (Figure 1) The difference in
total payer cost of the two scenarios (current mix minus new mix) represents the
budget impact of DMM therapy implementation.13,14 (Figure 1) In addition the study
estimated the total per-member-per-month (PMPM) AD treatment cost before and
after introduction of DMM therapy, determined by dividing the total cost by the
population at risk eligible to receive DMM and dividing result by 12 months13,14.
One-way sensitivity analyses were used to evaluate the impact of varying
parameters on total cost and the PMPM value. In our model the following parameters
were varied: percentage of AD patients on AD specific medications, price of DMM
therapy, percentage of new cases utilizing DMM, percentage of patients switching
from current therapy to DMM, and percentage of patients adding DMM to their
current therapy. Each parameter was varied from the default value by ±50% for each
of our parameters to estimate the lowest total cost and PMPM, and the highest total
cost and PMPM compared to the base-case assumptions. The model was built, and
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calculations estimated using Microsoft Excel.

2.4 Results
The total population at risk for Alzheimer’s disease (AD), in the Optum
Clinformatics™ Data Mart database, was approximately 2.6 million individuals (55
years and older). Among them we found 2,203 that had an AD diagnosis and enrolled
between the 2010-2012 years. Among those individuals a total of 436 patients (20%)
had AD specific medications filled e.g. Donepezil or Memantine filled during 2012.
Measuring utilization of AD medications (Table 1) and categorizing them by drug
class Acetylcholinesterase Inhibitors (AChEIs): Donepezil (Aricept), Galantamine
(Exelon), Rivastigmine (Razadyne),, and N-Methyl-D-Aspartate (NMDA):
Memantine (Namenda); patients received a total 5,088 prescriptions (Rx) of AD
medications. Among those prescriptions 1,526 (30%) Rx in 144 patients were for
AChEIs monotherapy with an average of 10.6 Rx filled per patient, 585 (11.5%) in 44
patients were for NMDA monotherapy with an average of 13.3 Rx filled per patient,
2,976 (58.5%) in 248 patients were for dual therapy of AChEIs plus NMDA with an
average of 12 Rx filled per patient. Mean costs per Rx for each of the drug class
categories are presented in Table 1: $147 per Rx filled in AChEIs monotherapy, $271
per Rx filled in NMDA monotherapy, and $209 per Rx filled in dual therapy of
AChEIs plus NMDA. Total cost of prescriptions among the various drug classes was
as follows: AChEIs monotherapy $224,380, NMDA monotherapy $158,589, and dual
therapy AChEIs plus NMDA $621,984 (Table 2)
After introduction of DMM (Table 1), 44 (2%) of our AD cohort (2,203) were
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considered newly diagnosed in health plan annually during the 2010-2012 years. The
study assumed switching of patients from current medication treatment to DMM as
well as adding DMM to current treatment; yielding an additional 88 (20%) patients
who switched and 45 (10%) that added DMM and bringing total amount of patients
receiving DMM therapy to 177. With each DMM patient receiving 1 Rx per month the
number of prescriptions added to the new treatment mix were 2,122 prescriptions, and
increasing total number of prescriptions to 6,159 ( 21% increase) after the addition of
DMM and subtracting the cost and number of prescriptions that switched therapy
(Table 2). We estimated new treatment mix total prescriptions 6,159: DMM 2,122
(34%), AChEIs monotherapy 1,208 (20%), NMDA monotherapy 461 (7.5%), and dual
therapy AChEIs plus NMDA 2,368 (38.5%). Total cost of prescriptions among the
new treatment mix was as follows: DMM $4,243,200, AChEIs monotherapy $177,534
NMDA monotherapy $125,052, and dual therapy AChEIs plus NMDA $494,961
(Table 2). Represented in Table 2 are costs of prescriptions before and after addition of
DMM, included are: total cost, per-member-per-month [PMPM], incremental cost
with total change. Total cost and PMPM before DMM was $1,004,954 [$0.0322]
compared to $5,040,748 [$0.1616] after DMM addition, with an incremental cost
change of $4,035,794 [$0.1294] an increase of 400%. The breakdown of cost by the
drug categories was as follows: DMM $0 before compared to $4,243,200 after,
AChEIs monotherapy $224,380 compared to $177,534 after DMM addition with an
incremental cost decrease of $46,846 (20.8%), NMDA monotherapy $158,589
compared to $125,052 after DMM addition with an incremental cost decrease of
$33,537 (21.1%), and dual therapy AChEIs plus NMDA $621,984 compared to
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$494,961 after DMM addition with an incremental cost decrease of $127,023 (20.4%).
Table 3 summarizes the findings from one-way sensitivity analyses in our new
treatment mix with a total cost of $5,040,748 and a PMPM $0.1616 as our base-case
assumptions. In our model the following parameters were varied: percentage of AD
patients on AD specific medications, price of DMM therapy, percentage of new cases
utilizing DMM, percentage of patients switching from current therapy to DMM, and
percentage of patients adding DMM to their current therapy. Each parameter was
varied from the default value by ±50% to estimate the lowest total cost and PMPM,
and the highest total cost and PMPM. Results were as follows; percentage of patients
with AD prescriptions: low value with 50% decrease was $3,050,774 [$0.0978] and
high value $7,030,723 [$0.0.2253], cost of DMM therapy: low value $2,919,148
[$0.0936] and high value $7,162,348 [$0.2296], percentage of new cases utilizing
DMM: low value $4,483,828 [$0.1437] and high value $6,101,548 [$0.1956]
percentage of patients switching current therapy to DMM: low value $4,090,401
[$0.1311] and high value $5,991,095 [$0.192], percentage of patients adding DMM to
current therapy: low value $4,510,348 [$0.1446] and high value $5,571,148 [$0.1786].
Figure 2 summarizes the PMPM findings of our one-way analyses using a
tornado diagram, ranking the parameters from most to least influence on our model
and overall outcome of total cost and PMPM. When the price of DMM was increased
by 50% the total cost increased by 42% (or by $0.068 PMPM). When percentage of
patients using AD medications was increased by 50% total cost increased by 39% (or
by $0.0637 PMPM). When new cases utilizing DMM was increased by 50% the total
cost increased by 21% (or by $0.034 PMPM). When percentage of patients switching
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to DMM was increased by 50% the total cost increased by 19% (or by $0.0304
PMPM). When percentage of patients adding DMM was increased by 50% the total
cost increased by 10.5% (or by $0.017 PMPM).
2.5 Discussion
Alzheimer’s disease (AD) has become one of the most financially taxing
chronic diseases on individuals, the health care system, and society.15-18 There is no
cure or treatment for AD with current available medications not impacting progression
of disease or slowing down cognitive decline.3,4 Future disease-modifying medications
(DMM) currently in clinical trials are the focus of the future treatment paradigm of
AD.4,5,19 In this study, with the perspective of a payer as our focus, we were able to
suggest that the future introduction of a DMM into a health care plan, or a formulary
list given that the new therapy is cost-effective will have a substantial increase on the
budgetary strategy of the health care systems. The overall budget model in our 2.6
million eligible population, using medication utilization and cost data from the Optum
Clinformatics™ Data Mart, revealed a budget impact of almost 4-fold, a 1 year budget
difference of before and after DMM introduction of approximately $4,035,796. Our
study estimated that prior to DMM introduction the per-member-per month (PMPM)
for AD prescription medications was $0.032, and increased by $0.129 after the
introduction of DMM for our health plan eligible population of 2.6 million patients.
For we are expecting these new DMM drugs to be priced at a premium, and despite
using a conservative estimate of the cost of DMM therapy the model’s sensitivity
analyses identified cost of DMM as the most influential parameter in the model. With
the introduction of DMM the total cost ranged from $2,919,148 to $7,162,348 when
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priced at $1,000 and $3,000 per prescription, respectively and a PMPM from $0.0936
to $0.2296. Considering that based on the various health plans and the amount
allocated in terms of PMPM for prescription medications, these PMPM values might
have an increased, decreased, or no effect on budgets once DMM is introduced.20-22
Most health plans medication benefits range between $25 to $35 PMPM.20 But, an
acceptable increase in PMPM for the implementation of a new therapy or drug to be
considered affordable for health plans is between 0.5%-1%, per the Institute for
Clinical and Economic Review (ICER) framework. In our study the increase in overall
cost was significant but when considering the PMPM impact on medication benefits,
will be within the acceptable 0.5%-1% range when using a $35 PMPM bench mark. In
terms of the substantial increase in overall cost, given the disease-modifying and
slowing down of disease progression properties associated with these new medications
can lead us to assume or expect; that an increase in the drug expenditure associated
with a DMM therapy may be offset by some of the savings resulting from effect of
drug in delaying institutionalized high costs. i.e. nursing homes.
In determining our model we decided to focus on AD prescription medication
cost and assumptions on the switching, and adding of DMM to future AD population.
The study’s focus was not to determine or estimate any off-setting costs or measure
the impact of other cost sources such as physician visits, hospital visits, or long-term
facility care. DMM therapy is expected to improve patients’ cognition, function, and
behavior but as to the implications that might have on utilization cost of other medical
services remains to be determined once the new therapy reaches the market.4,5,19,23,24
Budget impact models are essential methods used by health plans, and
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hospitals in determining effect and affordability of implementing a new therapy,
allowing decision- makers to evaluate both the clinical and economic implications on
medical and pharmacy budgets.13,20-23
2.6 Limitations
Potential limitation of the study was the percentage of patients switching from
current therapy or adding to their current therapy the new DMM medication. The
assumptions concerning the new treatment mix may or may not be representative of
what we might see in terms of utilization of a new DMM therapy. The model
assumptions concerning that there will be patients switching or adding or first time
users of DMM was reasonable, and that hospitals or other payers perform using
similar method when conducting their own budget impacts. Another potential
limitation was not including any costs other than medication cost, and not showing
any offsetting costs to other medical services, or side effect costs that introduction of
DMM might result in, but those would have been difficult to make educated
assumptions on and would have more reliable data once medication is on the market.
Further, we know that DMM specifically target patients in the early less severe stages
of AD and an assessment of disease severity could not be obtained from this database.
This might be essential in determining a more accurate representation on who would
be more eligible to use the new therapy. Being a commercial based health care plan
our results might not be generalized to government or other non-private health care
plans.
2.7 Conclusion
This study, to the best of our knowledge, is first to predict and quantify a
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budget impact for a proposed disease-modifying medication for the treatment of
Alzheimer’s disease. Our model demonstrated a substantial increase in the overall
total cost after the introduction of the new therapy. The study highlighted that the cost
of the new therapy will be the main cost factor to the impact seen in budget analyses
conducted in other health plans, and hospitals.
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Figure 1. Budget Impact Flowchart
CURRENT TREATMENT

NEW TREATMENT
Total Population at Risk
Alzheimer's Disease (AD)
(>=55 years old)
Optum Database (2010-2012)

Total Population at Risk
Alzheimer's Disease (AD)
(>=55 years old)
Optum Database (2010-2012)

Target Population:
Continous enrollment
(2010-2012) with AD
specific medications
filled during 2012

Target Population:
Continous enrollment
(2010-2012) with AD
specific medications
filled during 2012

Costs: AD specific prescriptions
filled in 2012. AChEIs and
NMDAs e.g. Donepezil and/or
Namenda
Plus cost of uptake for new
Disease-Modifying Medication

Costs: AD specific
prescriptions filled in
2012. AChEIs and
NMDAs e.g. Donepezil
and/or Namenda

Cost of New
Treatment Mix

Cost of Current
Treatment Mix

Difference=Budget Impact
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Table 1. Unit Costs Applied to Base-Case Analysis and Prescription Utilizations
Among the Drug Classes Before and After Introduction of Disease-Modifying
Medication (DMM)
BEFOR DMM¹

Resource

Rx²

Patients

Cost ($) /
Rx

Rx /
Patient

Reference

Alzheimer's
Medications

AChEIs³

1526

144

147

10.6

Optum Datamart™
(2014 $)

NMDA⁴

585

44

271

13.3

Optum Datamart™
(2014 $)

AChEI+NMDA

2976

248

209

12

Optum Datamart™
(2014 $)

Total

5088

436

AFTER DMM

Resource

Rx

Patients

Cost ($) /
Rx

Rx /
Patient

Reference

Alzheimer's
Medications
DMM

2122

177

2,000

12

AChEIs

1208

117

147

10.6

Optum Datamart™
(2014 $)

NMDA

461

35

271

13.3

Optum Datamart™
(2014 $)

AChEI+NMDA

2368

202

209

12

Optum Datamart™
(2014 $)

Total

6159

530

1- Disease-Modifying
Medication
2- Prescriptions
(Rx)
3- Acetylcholinesterase Inhibitors e.g.
Donepezil
4- N-Methyl-D-Aspartate e.g.
Namenda
* Calculation using assumptions of expected cost
and utilization of new drug
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Table 2. Total Budget Impact: Health Plan of 2.6 Million Members Before and
After Introduction of Disease-Modifying Medication (DMM)
Before DMM
Total ($) [PMPM]

After DMM Total
($) [PMPM]

Incremental Cost ($) Total
(% Change) [PMPM]

DMM¹

$0

$4,243,200

$4,243,200

AChEI²

$224,380

$177,534

$-46,846 (-20.8)

NMDA³

$158,589

$125,052

$-33,537 (-21.1)

AChEI+NMDA

$621,984

$494,961

$-127,023 (-20.4)

Total Costs

$1,004,954
[$0.0322]

$5,040,748
[$0.1616]

$4,035,794 (400)
[$0.1294]

Alzheimer's
Medications

PMPM=per member per month [(Total Cost /# of members
in health plan) / 12 months]
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Table 3. Sensitivity Analyses: Total Costs and Per-Member-Per-Month (PMPM)
Costs After Introduction of Disease-Modifying Medication (DMM)
Total Cost
Base Case

$5,040,748.69

Percentage Adding to DMM ±50%
Percentage Switching to DMM ±50%
New Cases for DMM Utilization
±50%
AD Medications Utilization ±50%
Cost of DMM ±50%
Total PMPM
Base Case

LOW
$4,510,348.69
$4,090,401.66

HIGH
$5,571,148.69
$5,991,095.72

$4,483,828.69
$3,050,774.34
$2,919,148.69

$6,101,548.69
$7,030,723.03
$7,162,348.69

$0.1616

Percentage Adding to DMM ±50%
Percentage Switching to DMM ±50%
New Cases for DMM Utilization
±50%
AD Medications Utilization ±50%
Cost of DMM ±50%
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LOW
$0.1446
$0.1311

HIGH
$0.1786
$0.1920

$0.1437
$0.0978
$0.0936

$0.1956
$0.2253
$0.2296

Figure 2. Tornado Diagram: Sensitivity Analyses Per-Member-Per-Month
(PMPM) Cost For Model Parameters After Introduction of Disease-Modifying
Medication (DMM)
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3.1 Abstract
Our purpose was to estimate direct cost of care for patients newly diagnosed
with Early-Onset Dementia (EOD), age 21-64 years old, and evaluating predictors on
total cost using a Generalized Linear Model (GLM). The sample was drawn from
Optum Clinformatics™ Data Mart, a large national insurer database with
administrative health claims information collected for up to 3 years from a private
health plan. Direct cost included cost for dementia-related services associated with
settings in: outpatient, inpatient, and long-term care, as well as prescription
medications for dementia. Patient characteristics, considered and analyzed by the
model, included age, gender, EOD subtypes, geography, and comorbidities. Total
direct cost per patient was $10,932 (SD $27,612) with a 66.7% increase in total cost
seen among patients in the Midwest, a 43.9% and 38.7% increase in patients age 32-42
years old and 43-53 years old, respectively. Total direct cost of EOD patients increased
considerably in various clinical and demographic variables. Age; 32-42 years-old, 4353 years old, Geography; Midwest region, Comorbidity; hypertension, depression, and
rheumatoid arthritis, were all associated with the highest direct cost..
3.2 Introduction
Dementia has become a public health concern given the U.S. aging population,
and although often associated with old age few studies estimate 220,000 to 640,000 of
Americans suffer from Early-Onset Dementia (EOD)1-3 comprising 1-5% of all
dementia cases. EOD is defined, arbitrarily, as individuals suffering from dementia
symptoms under the age of 65, while still having the same symptoms and subtypes as
seen in the older population in that Alzheimer’s Disease, Vascular Dementia, Lewy

58

Body Dementia, and Frontotemporal Dementia are all identified in EOD.1-3 EOD has
an impact affecting people in their productive years of life holding both professional
and personal responsibilities when the disease strikes them.3-5 The burden of disease is
both personal and economic, impacting the patients, their families, communities, and
the health care system. The literature is scarce regarding the prevalence and incidence
of EOD, and despite the high financial implication of dementia most of the analysis of
cost burden have paid little attention to EOD compared to dementia with age of onset
65 or older.3-6 This study aimed to provide information describing the direct cost of
care associated with EOD and how patient clinical and demographic characteristics
impact that total cost.
3.3 Methods
The primary data source was the Optum Clinformatics™ Data Mart, a large
national insurer database with administrative health claims information for
approximately 19 million patients, collected from January 2010 to December 2012.
Available information about these patients with private insurance included: member
demographics, medical claims, pharmacy claims, lab results, and inpatient claims.
The study population was comprised of patients with only a single subtype
EOD categorized by following etiologies: Mild Cognitive Impairment (MCI),
Alzheimer’s Disease (AD), Vascular Dementia (VD), Frontotemporal Lobar Dementia
(FTD), Lewy Body Dementia (LBD), and Dementia Non-Specific (DNOS) that does
not fit in the previous mentioned diagnoses.1,2 Age, gender, dementia subtypes,
geographic locations by states, and comorbidities were the patient characteristics
considered and analyzed.
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Population selection was as follows: diagnosis associated with EOD etiologies
in accordance with the International Classification of Disease 9th Edition Clinical
Modification [ICD-9-CM] medical codes. Relevant codes were reviewed and selected
from the Agency for Healthcare Research and Quality (AHRQ), using the Clinical
Classification Software (CCS) from the Healthcare Cost and Utilization Project
(HCUP). The Clinical Classification Software (CCS) for ICD-9-CM is a tool
developed for HCUP sponsored by AHRQ, which provides over 14,000 diagnosis
codes and 3,900 procedure codes. Continuous enrollment was required for a minimum
of 18 months to allow for a look back of 365 days to capture the newly diagnosed
cases, and then only consider the new cases that had a minimum of 12 month follow
up to estimate cost of care. Early-Onset newly diagnosed dementia patient ages’ 21 to
64 years old inclusive, and excluding any patients with a cancer diagnosis. Cancer
diagnosis is associated with high cost of care and would introduce bias in our cost
estimates for newly diagnosed EOD patients. To meet the newly diagnosed criteria we
concentrated on incident cases or first time diagnosis, which was determined by our
365 days look back period among patients with 18 months continuous enrollment.
Patients that recorded a diagnosis of dementia that was less than 365 days were
captured. This helped us make the assumption that the patients did not come into the
cohort with the diagnosis previously.
Two analytic samples were created comprising patients with EOD as primary,
secondary or any other diagnosis, and patients having EOD as their primary diagnosis
only. EOD as primary diagnosis only was used for cost analysis (i.e. expenses for
services associated with EOD care) and descriptive characteristics, while the group
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identified with EOD codes as primary or non-primary diagnoses was also analyzed to
describe characteristics of the overall EOD population. (Figure 1). Study outcome
(dependent variable) was total annual per-patient cost for all health care service use
associated with care for EOD, with independent variables represented by: age, gender,
EOD subtypes, geography, and comorbidities.
Age was grouped into separate categories: 21-31 years old (Category1), 32-42
(Category2), 43-53 (Category3), and 54-64 (Category4). Gender separated into male
and female. EOD subtypes were represented by: MCI, AD, LBD, VD, FTD, and
DNOS. Geography was categorized as U.S. regions: Northeast, South, Midwest, and
West. Comorbidities were defined and searched using the Elixhauser Comorbidities
Index having the following comorbidity items included:7 congestive heart failure,
cardiac arrhythmias, valvular disease, pulmonary circulation disorders, peripheral
vascular disorders, hypertension, paralysis, chronic pulmonary disease, diabetes,
hypothyroidism, renal failure, liver disease, peptic ulcer disease, AIDS/HIV,
rheumatoid arthritis, coagulopathy, obesity, weight loss, fluids and electrolyte
disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse,
psychoses, depression, other mental disorders. Patients were categorized as: no
comorbidity or any comorbidity, with any comorbidity representing patients with 0,1,
2 or more of the above searched comorbidities.
Total annual per-patient cost, as the dependent variable, included Outpatient
care, Inpatient stay, Long-Term Facility stay, and Prescription drugs were dementia
specific medications: Anticholinesterase Inhibitors (AChEIs) e.g. Donepezil, and
NMDAs e.g. Memantine, . Outpatient care included: office visits, home care, urgent
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care facility, outpatient hospital, and ambulatory surgical center. Inpatient stays
included sites: inpatient hospital, emergency room visits, inpatient psychiatric facility,
and partial hospitalization-psychiatric facility. Long-Term Facilities included: skilled
nursing home facility, nursing facility, custodial care facility. Outpatient, inpatient, and
long-term facilities were defined using the American Medical Association (AMA)
Current Procedural Terminology (CPT) Manual. Costs represented amount charged to
the insurer, minus patient coinsurance, copay or patient out of pocket payments
towards their deductible.
Differences in mean total costs between the variable categories were assessed
using an ANOVA test. While evaluating the relationship between total cost and
covariates of interest, and because of the skewed nature of cost, we utilized a
Generalized Linear Model (GLM).8-10 Predictors of cost were determined using the
GLM using a forward predictive approach, and implementing Modified Park test to
determine dependent variable distribution.8-10 GLM was best method for the model
using a “link” and “family” function due to skewed nature of the cost variable, and
since log transformation could not achieve normality using Ordinary Least-Squares
(OLS).8-11 We used the link function to specify the relationship between the mean of
our outcome variable, total cost, and predictors.8-11 While family function which
corresponds to the distribution of data which in this case was a Gamma distribution
informed by the Modified Park Test.8-11
For all analyses, statistical significance was considered a 2-sided P-value
<0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute,
Cary, NC). This study was reviewed and approved as exempt by the University of
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Rhode Island’s Institutional Review Board.
3.4 Results
The cohort sample was created after applying inclusion and exclusion criteria
(Figure 1): patients with primary diagnosis of any subtype of dementia (n=2,150) were
used for the descriptive statistics presented in Tables 1 and 2, health service utilization
(Table 3), and used for the development of the GLM used for our cost analysis.
We initially identified 42,226 patients, from total number of 19 million patients
with approximately 2 in 1,000 prevalence, having at least one primary or non-primary
diagnosis for dementia (Figure 1); from which 13,185 patients were excluded for not
being continuously enrolled for a minimum of 18 months. A further 21,120 patients
were excluded for being older than 64 years of age or younger than 21 years of age.
An additional 96 patients were excluded for having a cancer diagnosis.
In the sample frequency demographic (n=2150) of newly diagnosed EOD
patients in our Table 1, females comprised 1183 (55.03%) of the population while
males account for 967 (44.97%). The age variable was divided into four categories
with patients aged 54-64 years old comprising 1198 (55.7%) of the population
followed by those age 43-53 years old accounting for 516 (24%); while those age 3242 years old were 250 (11.62%), and accounting for the remaining cases were the 2131 years old with 186 (8.65%). As for the various dementia subtypes the frequencies
were as follows: MCI 1001 (46.55%), Dementia-NOS 762 (33.4%), AD 243 (11.3),
VD 101 (4.69%), FTD 30 (1.39%), and LBD 13 (0.61%). Dementia Non-Specific
(NOS) represents dementia that had a diagnosis code of dementia that did not fit any
of the other more specific subtypes. The majority of our population was found in the
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South 994 (46.23%), followed by the Midwest 444 (20.65%), and with the West and
Northeast at similar frequencies of 358 (16.65%) and 354 (16.64%), respectively.
Final variable of interest was comorbidity and whether patients had any of the
Elixhauser comorbidities, patients were divided into having; 0, 1, 2 or more
comorbidity. Patients with only 1 comorbidity accounted for 956 (44.4%), while
patients with 2 or more comorbidity recorded 661 (30.9%). The remaining group of
533 (24.7%) recorded no or 0 comorbidity. In our Table 2 (n=2,150) we provide
descriptive statistics of sample frequencies in patients categorized by dementia
subtypes.
Among patients with EOD documented as Mild Cognitive Impairment
(MCI, n=1001) we found a statistically significant difference by Geographical regions
(P-value<0.0001) with majority of our cohort residing in the South (n=467; 46.65%).
Most patients with MCI recorded at least 1 or more diagnosis for a relevant diagnosis,
showing statistically significant difference in Comorbidity variable (P-value=0.017).
MCI patients 240 (23.98%) documented no comorbidity, 477 (47.65%) accounted for
having 1 comorbidity only, and remaining 284 (23.67%) MCI patients recorded 2 or
more comorbidity. Differences in MCI prevalence by age or gender were not
statistically significant. (P-values=0.073 and 0.58, respectively).
Among patients having an EOD documented as Alzheimer’s Disease (AD,
n=243), there was no statistically significant difference in frequencies among the
various Age Categories (P-value=0.22), no difference in gender (P-value=0.05), no
difference among Geographical regions (P-value=0.58), and no statistically significant
difference between the Comorbidity Categories (P-value=0.27).
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Among patients with a diagnosis of Lewy Body Dementia (LBD, n=19),
Frontotemporal Dementia (FTD, n=49), and Vascular Dementia (VD, n=212) no
statistically significant difference (P-values >0.05) was found in the relationship of
having a diagnosis of one of those subtypes and in any of our variable of interests of;
Age, Gender, Geography, or Comorbidity.
Finally, among patients with Dementia-NOS (n=762) statistically significant
differences was found in Age, Geography, and Comorbidity. Age 54-64 years old was
the majority of Dementia-NOS patients at 405 (53.15%) and the least cases at 71
(9.32%) in the 21-31 years old category (P-value=0.04). Most of the Dementia-NOS
patients were located in the South 329 (43.18%) followed by the Midwest 189
(24.8%), the remaining split between Northeast 136 (17.85%) and West 108 (14.17%)
(P-value=0.0004). Dementia-NOS patients with 0 or no comorbidity were 184
(24.15%) followed by 312 (40.94%) with 1 comorbidity, and remaining 266 (16.79%)
with 2 or more comorbidity (P-value=0.013). Gender showed no statistically
significant difference in Dementia-NOS patients (P-value=0.16).
In Table 3 we present the frequency and percentage of patients utilizing
outpatient and inpatient services, long-term care and prescription medication for
dementia, for events associated with a primary diagnosis of dementia (n=2,150
patients). All patients had at least 1 outpatient visit for dementia, as this was a study
inclusion criterion, and thus we did not apply a test for statistical significance. Among
these 2,150 patients, 205 (9.5%) had at least 1 inpatient stay. A majority of these
patients (n=1001, 46.5%) were diagnosed with MCI, 30.7% had a diagnosis of
Dementia-NOS, while 11.3% had a diagnosis of AD. Statistically significant
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differences were observed among the frequency of inpatient stays by Geography (Pvalue=0.0008) with largest inpatient stays occurring in the South (n=94, 45.5%)
followed by the Midwest (n=61, 29.7%). Inpatient stay statistically significant
difference was seen in comorbidity categories (P-value <0.0001) with patients (n=105,
51.22%) having 2 or more comorbidity had an inpatient stay compared to patients
(n=89, 43.41%) with 1 comorbidity, and patients (n=11, 5.37%) having no or 0
comorbidity having an inpatient stay.
For Long-Term Facility (LTC) stay we have patients (n=43, 2%) that entered
LTC. Statistically significant differences, for LTC stay, in frequencies among the
variables was found in the Geography variable (P-value <0.0001) and Comorbidity
variable (P-value=0.0003). Patients (n=19, 44.1%) with LTC stay were found mostly
in the Midwest. Patients (n=23, 53.49%) with 2 or more comorbidity had LTC stay
compared to patients (n=19, 44.19%) that had 1 comorbidity having LTC stay.
Finally, patients (n=79, 3.6%) recorded prescription dementia drugs being
filled. Statistically significant differences in frequencies among the variables was
found in the Comorbidity categories (P-value=0.005). Patients (n=43, 54.43%) with 1
comorbidity recorded filling prescriptions for dementia medications compared to
patients (n=27, 34.18%) with no or 0 comorbidity, and patients (n=9, 11.39%) with 2
or more comorbidity when filling prescriptions for dementia medications. Some
notable counts captured showed that of the 79 prescriptions filled; 20 MCI patients, 25
AD patients, and 30 Dementia-NOS patients had dementia specific drugs filled.
Following the care setting frequencies we estimated the mean and total cost, in
dollars, of each care setting during a 12-month time frame for our new cases of

66

primary EOD diagnosis (n=2,150), as presented in Table 4.
Total cost for each setting was as follows: outpatient (n=2,150, 100%) was
approximately $16.1million, inpatient (n=205, 9.5%) was approximately $6.6million,
LTC (n=43, 2%) was $560,755 and Rx (n=79, 3.6%)) was $ 146,597 yielding a total
cost of care at approximately $23.5million for these 2,150 newly diagnosed patients
with primary EOD diagnosis. Mean cost per care setting when utilized by this cohort
(n=2,150) results in: outpatient cost approximately $7,524 (SD=$19,123), inpatient
cost approximately $3,079 (SD=$16,275), LTC cost approximately $260
(SD=$2,441), and total mean cost of all services approximately $10,932
(SD=$27,612).
These costs differ from the mean cost per patient in each care setting utilized,
yielding the following results: outpatient (n=2,150, 100%) cost approximately $7,524
(SD=$19,123), inpatient (n=205, 9.5%) cost approximately $32,300 (SD=$42,918),
LTC (n=43, 2%) cost approximately $13,040 (SD=$11,587), and Rx (n=79, 3.6%) cost
approximately $1,855 (SD=$2,427).
In Table 5 we provide descriptive statistics of the total cost given the specific
care settings in each of our variables, and determining statistical significance among
the variable categories’ cost using an ANOVA test.
Outpatient visits showing statistically significant differences were found in
patients with comorbidities (P-value <0.0001), where patients with no or 0
comorbidity averaged a direct cost of $2,469 (SD=$3,652) compared to patients with 1
comorbidity $8,819 (SD=$24,938), and $9,726 (SD=$20,327) in patients with 2 or
more comorbidity. No statistically significant difference was shown in outpatient visit

67

cost among the various Age categories (P-value=0.11), or in Gender (P-value=0.96),
or among the various dementia Subtypes (P-value=0.82), or Geographical regions (Pvalue=0.18).
Inpatient stay showing statistically significant differences were found among
the Age categories (P-Value=0.008) with 21-31 years old having a mean cost of
$66,159 (SD=$95,155), followed 54-64 years old with $31,614 (SD=$37,008), 43-53
years old at $28,685 (SD=$33,217), and the lowest mean cost of $17,892
(SD=$20,417) among32-42 years old. Statistically significant differences were shown
in Geographical regions (P-value=0.01) with the West averaging $48,335
(SD=$74,695), followed by the Northeast at $39,293 (SD=$49,094), the Midwest at
$38,811 (SD=$44,959), and the South at $22,526 (SD=$26,526). In addition,
statistically significant difference was shown in Comorbidity categories with $17,426
(SD=$2,791) in patients with 0 comorbidity compared to $24,803 (SD=$26,449) in
patients with 1 comorbidity, and $42,982 (SD=$56,427) in 2 or more comorbidity.
Gender (P-value=0.72), and dementia Subtype (P-value=0.06) all showed no
statistically significant differences in mean cost in each of the specific variable
categories for inpatient stay.
Long-Term Facility (LTC) stay, showed no statistically significant differences
in mean cost LTC stay among our variables of interest: Age (P-value=0.85), Gender
(P-value=0.94), dementia Subtypes (P-value=0.91), Geography (P-value=0.51), and
Comorbidity (P-value=0.43).
Prescription drugs (Rx), dementia specific medications, mean cost showed no
statistically significant differences among the variables of interest: Age (P-
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value=0.49), Gender (P-value=0.55), dementia Subtypes (P-value=0.94), and
Geography (P-value=0.68). Comorbidity (P-Value=0.01) showed statistically
significant differences in the mean cost, with $1,371 (SD=1,995) in patients with 0
comorbidity compared to $1,942 (SD=2,154) in patients with 1 comorbidity, and
$2,893 (SD=$4,254) with 2 or more comorbidity. All 79 patients with dementia
prescription drugs filled recorded No comorbidity.
Using GLM we identified several statistically significant (P-values <0.05)
predictors of cost as seen in Table 6: Age 43-53 years old, Midwest region, and
Comorbidity. Comorbidities with most impact included: Chronic Heart Failure (CHF),
Hypertension (HTN), Cardiac Arrhythmias (CARDARR), Psychoses (PSYCH),
Chronic Pulmonary Disease (CHRLUNG), Rheumatoid Arthritis (ARTH), Deficiency
Anemia (ANEMDEFF), Coagulopathy (COAG), Pulmonary Circulations
(PULMICRC), Peripheral Vascular Disorders (PERIVASC), Valvular Disease
(VALVE), Fluid and Electrolyte (LYTES).
The model developed estimated that mean direct total cost of care in newly
diagnosed patients with Early-Onset Dementia (EOD) was $10,932 (SD=$27,612); an
increase of up to 66.7% in patients living in the Midwest compared to the South as the
reference, increase of 38.7% in 43-53 years old when compared to the reference 2131 years old. Increases in mean total cost of care having specific comorbidities, when
compared to the absence of the comorbidity, were as follows: 664.1% (or 6.6 times) in
patients diagnosed with CHF as a comorbidity, 62.4 % (or 1.6 times) with HTN,
263.5% (or 2.63 times) with CARDARR, 62.2% (or 1.6 times) with PSYCH, 82.2%
(or 1.8 times) with CHRNLUNG, 87.8 % (or 1.8 times) with ARTH, 101.4% (or 2
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times) with ANEMDEFF, 148.5% (or 2.5 times) with COAG, 318% (or 3.1 times) with
PULMCIRC, 125.6% (or 2.2 times) with PERIVASC, 155.7 % (or 2.5 times) with
VALVE, and 324.1% (or 3.2 times) with LYTES.
Our Table 7 compares the mean cost of all the significant predictors, from our GLM,
versus the mean cost of the reference compared with. In Age category (reference 2131 years old vs predictor 43-53 years old); $10,474 (SD=$37,106) vs $12,078
(SD=$27,448), Region Category (reference South vs predictor Midwest); $9,812
(SD=$20,771) vs $15,081 (SD=$40,509), CHF comorbidity (reference CHF absent vs
CHF present); $10,061 (SD=$25,730) vs $53,609 (SD=$62,528), HTN; $10,062
(SD=$28,724) vs $13,154 (SD=$24,426), CARDARR; $9,410 (SD=$25,927) vs
$24,284 (SD=$36,891), PSYCH; $10,823 (SD=$27,514) vs $17,929 (SD=$33,012),
CHRNLUNG; $10,788 (SD=28,177) vs $13,177 (SD=17,309), ARTH; $10,924
(SD=$27,754) vs $11,570 (SD=$13,418), ANEMDEFF; $10,710 (SD=$27,079) vs
$16,620 (SD=$38,622), COAG; $10,894 (SD=$27,624) vs $16,429 (SD=$26,042),
PULMCIRC; $10,646 (SD=$27,112) vs $31,146 (SD=$39,171), PERIVASC;
$10,771.39 (SD=$27,440) vs $25,238 (SD=38,117), VALVE; $10,596 (SD=$27,546)
vs $21,078 (SD=$28,749), LYTES; $10,523 (SD=$26,204) vs $32,511 (SD=$66,268).
Dementia patients with 1 or more comorbidities can expect an increased overall cost
of care, with cardiac comorbidities being the greatest contributors to cost.
3.5 Discussion
In this study, we estimated the total direct mean cost for disease specific
patients with Early-Onset Dementia (EOD), and determined patients’ clinical and
demographic predictors of the overall care cost. The purpose of our study was to
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provide a source of cost information for an underrepresented population in studies
conducted in both cost, and epidemiology fields.1,3,12,13 We estimated an annual perpatient direct cost for medical care among newly diagnosed cases of EOD of $10,932
(SD=$27,612). In addition we have the cost breakdown for each of the medical care
settings, providing context and cost information to guide allocation of resources when
planning healthcare services for patients with EOD. With cost analyses for EarlyOnset Dementia difficult to find we relied on cost information studies for Dementia
and Alzheimer’s in Late-Onset (>65years) patients to compare with our findings.
Given that there currently no treatment is available for dementia the type of care
setting and services for both Early-Onset and Late-Onset are expected to be
similar.13,14 Zhu et al., in a 2006 Alzheimer’s study consisting of a cohort across 3 US
medical facilities found a total direct mean cost per-patient equal to $12,587
(SD=$20,849) over a 4 year period. This study categorized care settings as: outpatient
treatment, hospitalization, and medications with no Long-term Facility cost
recorded.15,16 In a 2011 systemic literature review study, by Mauskopf and Mucha, on
direct and indirect medical and non-medical cost across the different level of severity
in Alzheimer’s disease; found that the mean direct cost in mild Alzheimer’s in 19
studies from 1993-2009 ranged approximately between $4,000 to as high as $19,000
per patient. Most of the studies collected by Mauskopf categorized the direct cost
under outpatient, inpatient, medications and with a few including cost of Long-Term
Facility care.17 Murman et al. 2007 in evaluating the direct cost of care in degenerative
dementia patients found an approximate mean of $17,000. In the Murman study
Nursing Home care costs were included in addition to the outpatient, inpatient, and
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medication costs.18,19
Our study focused on the total cost increases of the medical care settings that
occurred in patients with specific clinical and demographic characteristics. In this 12
month period higher costs were associated with ages 43-53 years old, the Midwest
region, and specific comorbidities. Dementia subtype patients were diagnosed with
were not a predictor of cost, and neither was gender.
The majority, approximately 75%, of new cases with EOD as a primary
diagnosis in our patient population, were diagnosed as either Mild Cognitive
Impairment (MCI) or DNOS and 10% having an Alzheimer’s disease (AD) diagnosis.
In this study the variable of Gender showed no statistically significant difference in
terms of frequency of medical care setting utilization or their cost, or in frequencies
among the various dementia subtypes except in AD were more females (60%) than
males (40%) where diagnosed (P-value=0.05).
In this study we showed a direct relationship between increased cost of care in
EOD patients per number comorbidities. We included each of the captured
comorbidities into our model to estimate the ones associated with higher costs. Results
showed that:
congestive heart failure (CHF), hypertension (HTN), Cardiac Arrhythmias
(CARDARR), Psychoses (PSYCH), Chronic Pulmonary Disease (CHRLUNG),
Rheumatoid Arthritis (ARTH), Deficiency Anemia (ANEMDEFF), Coagulopathy
(COAG), Pulmonary Circulations (PULMCIRC), Peripheral Vascular Disorders
(PERIVASC), Valvular Disease (VALVE), and Fluid and Electrolyte Disorders
(LYTES) were associated with increased cost of care. In Figure 2 all the predictor
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costs were plotted against our total mean cost $10,932 (SD=$27,612), and having
Congestive Heart Failure (CHF), Cardiac Arrhythmias (CARDARR), and three other
comorbidities as the predictors showing statistically significant difference from our
total mean cost $10,932 (SD=$27,612). Patients with cardiac comorbidities can expect
an increased utilization of care settings and producing the higher costs.
We found cost differences across Geographical regions, attributed to
differences seen in terms of care setting utilizations and cost among dementia patients
across the US.20-23 Patients in the Midwest showed the highest cost when compared to
the other three regions of the country. These variations in cost across regions may be
due to regional pricing differences, availability of services, socioeconomic differences,
ethnic and racial differences which would need further examination16,20-23.
We found the most frequent EOD was either MCI or DNOS, but with none of
the types being a predictor of cost in our overall model. Expectations was that AD
would account for majority of the diagnosis given that the few estimations found in
the literature show that AD would account for about 30% of all EOD.3,5,6,23 In addition
most of the cost analyses done specifically target dementia and AD in ages 65 and
older making it difficult to have comparable values in EOD patients, and relying on
the assumption and the expectation that costs seen in EOD, and specifically AD,
mirror what is produced in the older patient groups.
3.6 Limitations
There are several limitations in our study. The database did not provide
information on race, education level, income or marital status, and these factors may
have been associated with cost differences. The cost information collected was total
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direct cost for dementia care, and not incremental costs associated with development
of the disease. In order to produce the incremental cost we would have to develop a
non-EOD patient group with similar characteristics of those of our EOD to show the
increasing or decreasing cost between developing EOD and not having EOD.
However, this was not the main concern of the study as we were trying to provide a
descriptive informative review on direct costs associated with services for EOD and its
subtypes. Being a commercial based health care plan our results might not be
generalized to government or other non-private health care plans.
3.7 Conclusion
Results of our study provided needed information for the direct cost in EarlyOnset Dementia patients. The study highlighted the significant variation of cost
estimates for the different care settings of interest, and producing a total mean direct
cost of care $10,932 (SD=$27,612) per patient. The study in addition provided an
understanding of predictors associated with higher cost in the Early-Onset Dementia
population; where patients with specific comorbidities were associated with increased
cost, patients 43-53 years old recorded higher mean cost, and patients living in the
Midwest region of the U.S. seen with higher costs. In providing these type of cost-ofillness studies decision makers are more informed as to the implications, and
distribution of these direct cost on the Early-Onset Dementia population.
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Figure 1. Population Flowchart
OPTUM DATA (2010-2012)
All Dementia events having a single
1° or 2° or 3° or 4° or 5° diagnosis of
any of the Dementia Subtypes:
Alzheimer's Disease, Lewy Body Disease,
Frontotemporal Dementia, Vascular Dementia
and Dementia Non-Specified
(N=42,226)

Continous Enrollment for a minimum of 18 months
(N=29,041)

NO

Exclusion:
(N=13,185)

Age 21 to 64 years old, inclusive
(N=7,921)

NO

Exclusion:
(N=21,120)

Patients with no Cancer Diagnosis
(N=7,825)

NO

Exclusion:
Patients with Cancer Diagnosis
(N=96)

Patients with diagnosis first date < 365 days
and has follow-up minimum of 12 months
(N=4,902)

NO

Patients with 1° diagnosis
(N=2,150)
*Cohort used for cost analysis
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Exclusion:
(N=2,923)

Table 1. Sample Frequency Demographic and Clinical Characteristics of Newly
Diagnosed Early-Onset Dementia (EOD) patients
Sample Size (N)

2150

Variables
Age Category, Yrs, N (%)
21-31

186 (8.65%)

32-42

250 (11.62%)

43-53

516 (24%)

54-64

1198 (55.7%)

Gender, N (%)
Female

1183 (55.03%)

Male

967 (44.97%)

Subtypes, N (%)
MCI¹

1001 (46.55%)

AD²

243 (11.3%)

LBD³

13 (0.61%)

FTD⁴

30 (1.39%)

VD⁵

101 (4.69%)

Dementia NOS⁶

762 (35.44%)

Geography, N (%)
Northeast

354 (16.46%)

South

994 (46.23%)

Midwest

444 (20.65%)

West

358 (16.65%)

Comorbidity, N (%)
No Comorbidity

533 (24.7%)

1

956 (44.4%)

2 or more⁷

661 (30.9%)

1 - Mild Cognitive Impairment
2 - Alzheimer's Disease
3 - Lewy Body Disease
4 - Frontotemporal Dementia
5 - Vascular Dementia
6 - Dementia Non-Specific characteristic under senile or
pre-senile dementia
7- Had at least 2 and up to 4 comorbidities
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Table 2. Descriptive Statistics of Sample Frequency Demographic and Clinical
Characteristics in Newly Diagnosed Patients with specific Early-Onset Dementia
Subtypes

Sample Size
(N=2150)
Variables

Age Category,
Yrs, N (%)
21-31

MCI

AD

LBD

FTD

VD

1001(46.55%)

243 (11.3%)

13 (0.61%)

30 (1.39%)

101 (4.69%)

Dementia
NOS
762 (33.4%)

86 (8.59%)

22 (9.05%)

< 5**

<5

<5

71 (9.32%)

32-42

105 (10.49%)

24 (9.88%)

<5

<5

12 (11.88%)

43-53

264 (26.37%)

48 (19.75%)

<5

7 (23.33%)

17 (16.83%)

54-64

546 (54.55%)

149 (61.32%)

11 (84.62%)

19 (63.33%)

68 (67.33%)

0.073

0.22

Not
Reported

0.77

0.05

107
(14.04%)
179
(23.49%)
405
(53.15%)
0.04*

Female

557 (55.64%)

148 (60.91%)

4 (30.77%)

14 (46.67%)

56 (55.45%)

Male

444 (44.36%)

95 (39.09%)

9 (69.23%)

16 (53.33%)

45 (44.55%)

0.58

0.05

0.07

0.35

0.93

Northeast

158 (15.78%)

36 (14.81%)

<5

6 (20%)

18 (17.82%)

South

467 (46.65%)

120 (49.38%)

7 (53.85%)

15 (50%)

56 (55.45%)

Midwest

175 (17.48%)

52 (21.41%)

<5

8 (26.67%)

17 (16.83%)

West

201 (20.08%)

35 (14.4%)

<5

1 (3.33%)

10 (9.9%)

P-Value

<0.0001*

0.58

Not
Reported

0.25

0.12

Comorbidity, N
(%)
No Comorbidity

240 (23.98%)

73 (30.04%)

<5

10 (33.33%)

22 (21.78%)

1

477 (47.65%)

104 (42.8%)

5 (38.46%)

16 (53.33%)

42 (41.58%)

2 or more

284 (23.67%)

66 (12.76%)

<5

4 (13.34%)

37 (36.64%)

0.017*

0.27

0.07

0.19

0.11

P-Value

Gender, N (%)

P-Value

404
(53.02%)
358
(46.98%)
0.16

Geography, N (%)

P-value
* p < 0.05
** < 5 are cells
that recorded
under 5 counts
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136
(17.85%)
329
(43.18%)
189 (24.8%)
108
(14.17%)
0.0004*

184
(24.15%)
312
(40.94%)
266
(16.79%)
0.013*

Table 3. Descriptive Statistics of Utilization given the specific Care Setting in
Early-Onset Dementia Patients
Outpatient¹

Inpatient²
205 (9.53%)

Long Term Care³
(LTC)
43 (2%)

Prescription Drugs⁴
(Rx)
79 (3.67%)

2150 (100%)

Age Category, Yrs, N (%)
21-31
32-42
43-53
54-64
P-Value

186 (8.65%)
250 (11.62%)
516 (24%)
1198 (55.7%)

15 (7.31%)
16 (7.8%)
54 (26.34%)
120 (58.53%)
0.245

< 5**
<5
9 (20.93%)
30 (69.76%)
0.281

<5
<5
<5
76 (96.21%)
Not reported

Gender, N (%)
Female
Male
P-Value

1183 (55.03%)
967 (44.97%)

107 (52.19%)
98 (47.81%)
0.391

19 (44.18%)
24 (55.82%)
0.149

41 (51.9%)
38 (48.1%)
0.569

Subtypes, N (%)
MCI
AD
LBD
FTD
VD
Dementia NOS
P-Value

1001 (46.55%)
243 (11.3%)
13 (0.61%)
30 (1.39%)
101 (4.69%)
762 (35.44%)

63 (30.73%)
21 (10.24%)
3 (1.46%)
3 (1.46%)
17 (8.29%)
98 (47.8%)
<0.0001*

<5
<5
<5
<5
<5
33 (76.74%)
Not reported

20 (25.31%)
25 (31.64%)
<5
<5
<5
30 (37.97%)
Not reported

Geography, N (%)
Northeast
South
Midwest
West
P-Value

354 (16.46%)
994 (46.23%)
444 (20.65%)
358 (16.65%)

31 (15.12%)
94 (45.58%)
61 (29.75%)
19 (9.26%)
0.0008*

12 (27.9%)
10 (23.25%)
19 (44.18%)
2 (4.65)
<0.0001*

8 (10.12%)
37 (46.83%)
18 (22.78%)
16 (20.25%)
0.419

Comorbidity, N (%)
No Comorbidity
1
2 or more
P-value

533 (24.7%)
956 (44.4%)
661 (30.9%)

11 (5.37%)
89 (43.41%)
105 (51.22%)
<0.0001*

<5
19 (44.19%)
23 (53.49%)
<0.0001*

27 (34.18%)
43 (54.43%)
9 (11.39%)
0.005*

Sample Size (N=2150)
Variables

1 - Outpatient includes : Physician Office Visits, Urgent Care Facility, Ambulatory Center, and Outpatient Hospital
2 - Inpatient includes : Inpatient Hospital, Emergency Room Visits
3 - Long Term Care includes : Home Care, Skilled Nursing, Nursing facility
4 - Prescription Drugs : Dementia Specific Medications (AChEIs, and NMDAs)
* p < 0.05
** < 5 are cells that
recorded under 5 counts
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Table 4. Mean and Total Cost ($) of Care Settings in Early-Onset Dementia
Patients during a 12-Month Time Period
Outpatient

Inpatient

LTC

Rx

Sample Size (N=2,150)

2150

205

43

79

Total Cost of service, ($)

$16,176,849

$6,621,504

$560,755

$146,597

$23,505,699

Mean Cost per service, $ (SD)
denominator N=2150

$7,524.11
(19,123.13)

$3,079.77
(16,275.37)

$260.8
(2,441.08)

$68.18
(579.56)

$10,932.88
(27,612.16)

Mean Cost per patient using the
service, $ (SD)
denominator N=patient size
utilizing service

$7,524.11
(19,123.13)

$32,300.02
(42,918.16)

$13,040.82
(11,587.33)

$1,855.66
(2,427.94)

Median Cost per patient, $

$3,098.46

$16,878.82

$9,048.66

$1,098.24
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Total

$3,378.97

Table 5 Descriptive Statistics of Total Mean Cost ($) of Care Settings in
Demographic and Clinical Characteristics of Early-Onset Dementia Patients,
during a 12-month Time Period
Sample Size
(N=2150)
Age Category,
Yrs
21-31

Outpatient
2150

Inpatient
205

LTC
43

Rx
79

Total

Cost (SD)

Cost (SD)

Cost (SD)

Cost (SD)

Cost (SD)

$4,974.12
(9,892.24)
$7,864.38
(3,9064.30)
$8,797.30
(19,197.17)
$7,300.63
(12,791.84)
0.11

$66,159.67
(95,155.66)
$17,892.27
(20,417.68)
$28,685.87
(33,217.94)
$31,614.97
(37,008.05)
0.008*

$15,317.13
(11,853.90)
$16,991.25
(21,832.58)
$15,042.08
(12,966.71)
$12,025.32
(11,092.65)
0.85

Not Reported

$10,474.28
(37,106.44)
$9,145.42
(40,010.68)
$12,077.99
(27,448.39)
$10,883.88
(22,306.49)
0.57

Cost (SD)
$7,541.21
(14,163.91)
$7,503.20
(23,834.04)

Cost (SD)
$33,308.78
(42,980.62)
$31,198.63
(43,043.54)

Cost (SD)
$13,186.11
(11,975.55)
$12,925.79
(11,528.82)

Cost (SD)
$2,034.04
(2,416.60)
$1,663.2 (2,408.93)

Cost (SD)
$10,836.20
(24,293.10)
$11,051.17
(31,208.87)

P-Value

0.96

0.72

0.94

0.55

0.85

Subtypes
MCI

Cost (SD)
$7,850.47
(16,656.54)
$6,820.32
(12,519.70)
$11,971.27
(17,851.8)
$5,044.45
(6,491.23)
$8,319.39
(13,275.53)
$7,236.08
(24,237.09)
0.82

Cost (SD)
$22,600.05
(25,813.02)
$50,025.70
(61,189.08)
$12,738.66
(15,101.26)
$13,860.80
(9,184.72)
$23,353.46
(18,996.03)
$34,452.6
(49,169.75)
0.06

Cost (SD)
$10,531.03
(14,357.78)
Not Reported

Cost (SD)
$2,089 (1,939.95)

Cost (SD)
$9,356.67
(20,683.45)
$11,394.1
(28,682.89)
$15,445.58
(20,000.46)
$6,624.18
(8,116.48)
$12,939.82
(21,248.75)
$12,683.02
(35,399.03)
0.15

Cost (SD)
$6285.54
(10,180.29)
$7,495.41
(14,910.14)
$9,094.66
(31,278.94)
$6,880.73
(16,168.75)
0.18

Cost (SD)
$39,293.52
(49,094.29)
$22,526.86
(26,187.76)
$38,811.54
(44,959.15)
$48,335.62
(74,695.18)
0.01*

Cost (SD)
$18,880.99
(11,826.98)
$10,804.56
(10,161.16)
$13,396.36
(12,527.94)
$3,803.4
(5,131.11)
0.51

Cost (SD)
$1,209.55
(1,473.27)
$2,101.79
(2,842.71)
$2,016.21 (2661.29)

Cost (SD)
$2,469.39
(3,652.19)
$8,819.62
(24,938.58)
$9,726.33
(20,327.32)
<0.0001*

Cost (SD)
$17,426.28
(2,0791.91)
$24,803
(26,449.14)
$42,982.79
(56,427.07)
0.02*

Cost (SD)
Not Reported

Cost (SD)
$1,371.4 (1995.98)

$11,076.75
(12,732.15)
$15,128.21
(10,517.08)
0.43

$1,942.41
(2,154.94)
$2,893.96
(4,254.73)
0.01*

32-42
43-53
54-64
P-Value
Gender
Female
Male

AD
LBD
FTD
VD
Dementia
NOS
P-Value
Geography
Northeast
South
Midwest
West
P-value
Comorbidity
No
Comorbidity
1
2 or more
P-Value

Not Reported
Not Reported
$17,413.63
(13,342.06)
$12,973.29
(11,655.24)
0.91

* p < 0.05
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Not Reported
$2,806.93
(2,026.10)
$1,818.11
(2,446.13)
0.49

$1,876.48
(2,512.71)
Not Reported
$1,452.37
(1,045.95)
Not Reported
$1,736.52
(2,824.20)
0.94

$1,428.98
(1,273.62)
0.68

Cost (SD)
$10,292.17
(24,023.40)
$9,812.65
(20,771.89)
$15,081.88
(40,509.44)
$9,531.14
(24,479.61)
0.05
Cost (SD)
$2,902.92
(5777.2)
$13,128.66
(35,275.14)
$14,232.13
(24,189.9)
<0.0001*

Table 6. Generalized Linear Model Predictors of Total Direct Costs
Co-efficient

Standard
Error (SE)

95% Confidence Interval

P-value

Marginal
Effect¹

GLM Parameters
Age Category Yrs,
(ref 21-31)
32-42

0.0062

0.1367

(-0.2168, 0.2742)

0.9636

43-53

0.3272

0.1141

(0.1036, 0.5507)

0.0041*

54-64

0.2063

0.1121

(-0.0134, 0.426)

0.0657

Region
(ref, South)
Midwest

0.5116

0.0742

(0.3662, 0.657)

<0.0001*

Northeast

0.0478

0.0872

(-0.1232, 0.2188)

0.5838

West

-0.0126

0.0869

(-0.1828, 0.1576)

0.8845

2.036

0.1947

(1.6501, 2.4133)

<0.0001*

664.1

0.4854

0.0648

(0.3585, 0.3124)

<0.0001*

62.4

1.2906

0.0927

(1.1088, 1.4724)

<0.0001*

263.5

0.4839

0.2226

(0.0477, 0.9201)

0.029*

62.2

0.1115

(0.3816, 0.8185)

<0.0001*

82.2

0.2354

(0.1698, 1.0926)

0.007*

87.8

0.1453

(0.4153, 0.985)

<0.0001*

101.4

0.3266

(0.2758, 1.5563)

0.0005*

148.5

0.231

(0.9779, 1.8833)

<0.0001*

318.1

0.2578

(0.3083, 1.319)

0.0016*

125.6

0.1544

(0.6364, 1.2418)

<0.0001*

155.7

0.2084

(1.0365, 1.8534)

<0.0001*

324.1

Comorbidity
(ref, Comorbidity
Absent)
Congestive Heart
Failure (CHF)
Hypertension (HTN)
Cardiac Arrhythmias
(CARDARR)
Psychoses (PSYCH)

Chronic Pulmonary
0.6001
Disease
(CHRNLUNG)
Rheumatoid Arthritis
0.6312
(ARTH)
Deficiency Anemia
0.7002
(ANEMDEFF)
Coagulopathy
0.916
(COAG)
Pulmonary
1.4306
Circulations
(PULMCIRC)
Peripheral Vascular
0.8136
Disorders
(PERIVASC)
Valvular Disease
0.9391
(VALVE)
Fluid and Electrolyte
1.445
Disorders (LYTES)
1 - Marginal Effect represents the %
increase in total cost when variable was
present
* p<0.05
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38.7

66.7

Table 7. Mean Cost, $, Comparison between the Predictors of Total Mean Cost
versus Mean Cost of Reference Variable, during a 12-month Time Period
Mean Cost, $ (reference) vs Mean Cost, $ (predictor)

95% Confidence
Interval (predictor)

Sample Size
(N=2,150)

Significant
Predictors*
Age Category, Yrs
(ref 21-31)
32-42*

$9,145 (SD=$28,014) vs $9,338 (SD=40,010)

($8,446, $12,945)

N=250

43-53

$10,474 (SD=$37,106) vs $12,078 (SD=$27,448)

($9,704, $14,451)

N=516

54-64

$10,883 (SD=$35,225) vs 11,544 (SD=$25,389)

($9,328, $13,784)

N=1198

Region
(ref, South)
Midwest*

$9,812 (SD=$20,771) vs $15,081 (SD=$40,509)

($11,303, $18,860)

N=444

Northeast

$9,474 (SD=$19,225) vs $10,292 (SD=24,023)

($9,105, $15,226)

N=358

West

$8,755 (SD=$23,555) vs $9,531 (SD=$15,331)

($8,066, $15,116)

N=354

$10,061 (SD=$25,730) vs $53,609 (SD=$62,528)

($34,365 , $72,825)

N=43

$10,062 (SD=$28,724) vs $13,154 (SD=$24,426)

($11,204 , $15,105)

N=605

Cardiac Arrhythmias
(CARDARR)*
Psychoses (PSYCH)*

$9,410 (SD=$25,927) vs $24,284 (SD=$36,891)

($19,382 , $29,186)

N=220

$10,823 (SD=$27,514) vs $17,929 (SD=$33,012)

($6,224 , $29,635)

N=33

Chronic Pulmonary
Disease
(CHRNLUNG)*
Rheumatoid Arthritis
(ARTH)*
Deficiency Anemia
(ANEMDEFF)*
Coagulopathy
(COAG)*
Pulmonary
Circulations
(PULMCIRC)*
Peripheral Vascular
Disorders
(PERIVASC)*
Valvular Disease
(VALVE)*
Fluid and Electrolyte
Disorders (LYTES)*

$10,788 (SD=28,177) vs $13,177 (SD=17,309)

($10,263 , $16,091)

N=138

$10,924 (SD=$27,754) vs $11,570 (SD=$13,418)

($6,446 , $16,674)

N=29

$10,710 (SD=$27,079) vs $16,620 (SD=$38,622)

($8,080 , $25,160)

N=81

$10,894 (SD=$27,624) vs $16,429 (SD=$26,042)

($2,007 , $30,851)

N=15

$10,646 (SD=$27,112) vs $31,146 (SD=$39,171)

($16,519 , $45,772)

N=30

$10,771.39 (SD=$27,440) vs $25,238 (SD=$38,117)

($9,142 , $41,333)

N=24

$10,596 (SD=$27,546) vs $21,078 (SD=$28,749)

($14,172 , $27,985)

N=69

$10,523 (SD=$26,204) vs $32,511 (SD=$66,268)

($11,318 , $53,705)

N=40

Comorbidity
(ref, Comorbidity
Absent)
Congestive Heart
Failure (CHF)*
Hypertension (HTN)*
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Figure 2. Cost of Predicators, in dollars, Compared to Overall Total Mean Cost,
during a 12-month Time Period

ARTH – Rheumatoid Arthritis
AgeCat3 – 43-53 years old
CHRNLUNG – Chronic Pulmonary Disease
HTN – Hypertension
Midwest – Region in U.S.
COAG – Coagulopathy
ANEMDEFF – Deficiency Anemia
PSYCH – Psychosis
VALVE – Valvular Disease
CARDARR – Cardiac Arrhythmias*
PERIVASC – Peripheral Vascular Disorder*
PULMCIRC – Pulmonary Circulations*
LYTES – Fluid and Electrolytes Disorders*
CHF – Congestive Heart Failure*
* Predictors that have a mean cost statistically significantly different than the total mean cost
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APPENDIX A. International Classification of Disease 9th [ICD-9] Edition medical
codes - Agency for Healthcare Research and Quality (AHRQ), using the Clinical
Classification Software (CCS) from the Healthcare Cost and Utilization Project
(HCUP)
Alzheimer’s disease: 331.0
Frontotemporal Dementia: 331.19
Dementia with Lewy Body: 331.82
Mild Cognitive Impairment: 331.83
Vascular Dementia, Uncomplicated:
290.40
Vascular Dementia, with Delirium:
290.41
Vascular Dementia, with Delusion:
290.42
Vascular Dementia, with Depressed Mood:
290.43
Senile Dementia, Uncomplicated:
290.0
Senile Dementia, with Delusional Features:
290.20
Senile Dementia, with Depressive Features:
290.21
Senile Dementia, with Delirium: 290.3
Pre-Senile Dementia, Uncomplicated: 290.10
Pre-Senile Dementia, with Delirium: 290.11
Pre-Senile Dementia, with Delusional Features: 290.12
Pre-Senile Dementia, with Depressive Features: 290.13
Dementia in Conditions Classified Elsewhere, without Behavioral Disturbance:
294.10
Dementia in Conditions Classified Elsewhere, with Behavioral Disturbance:
294.11
Dementia, Unspecified, without Behavioral Disturbance:
294.20
Dementia, Unspecified, with Behavioral Disturbance:
294.21
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